Stay updated with breaking news from Stephan Jackman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ATLANTA--(BUSINESS WIRE)--$ACAD #ALZN002--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder, major depressive disorder (“MDD”) and post-traumatic stress di...
Alzamend Neuro expects top-line data in June for its completed Phase 2 trial of a lithium formulation for Alzheimer’s and other diseases.
A biopharmaceutical company and the Miller School of Medicine at the University of Miami have announced a partnership to conduct a phase 1/2a clinical trial of ALZN002, a treatment for Alzheimer’s-related dementia.According to a release from Alzamend Neuro, ALZN002 is a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the
Alzamend Neuro, Inc. , an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease , bipolar disorder, major depressive... | October 31, 2022
Alzamend Neuro Inc (NASDAQ:ALZN) CEO and director Stephan Jackman speaks to Proactive about the two therapeutics the company is currently working to...